All In Biotech

Drug Trial Radar · NCT06425926

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

117

Planned (sponsor's estimate)

Start

May 9, 2024

Primary completion

Dec 2026

Study completion Nov 2027

Sponsor

Lead sponsor
Georgiamune IncIndustry
Sponsor type
Industry
First posted
May 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).

Conditions

  • Melanoma Stage IV
  • Solid Tumor

Interventions

  • GIM-531Drug

    GIM-531 administered orally daily

  • Anti-PD-1 monoclonal antibodyDrug

    Continued treatment with anti-PD-1 therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs) / serious adverse events (SAEs) and tolerabilityTime frame: Through study completion, an average of 1 year
  2. Dose limiting toxicities (DLT) with GIM-531Time frame: 21 days

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona · Recruiting

  • Comprehensive Blood and Cancer Center

    Bakersfield, California · Recruiting

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate

    Los Angeles, California · Recruiting

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana

    Billings, Montana · Recruiting

  • Weill Cornell Medicine - New York Presbyterian Hospital

    New York, New York · Recruiting

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio · Recruiting

  • Tennessee Oncology, PLLC

    Nashville, Tennessee · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.